US Patent

US11400087 — Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function

Method of Use · Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2033-09-24 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of starting aripiprazole treatment in patients with impaired CYP2D6 or CYP3A4 enzyme function.

USPTO Abstract

The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.

Drugs covered by this patent

Abilify (aripiprazole) · Generic (originally Otsuka/BMS)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-814`	—	Abilify
`U-3245`	—	Abilify
`U-814`	—	Abilify
`U-814`	—	Abilify

Patent Metadata

Patent number: US11400087
Jurisdiction: US
Classification: Method of Use
Expires: 2033-09-24
Drug substance claim: No
Drug product claim: No
Assignee: Otsuka Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.